

Flash therapy [.. mostly FRIDA]

A. Sarti

Retreat della sezione INFN di Roma







WARNING Disturbing Content! Viewer Discretion is Advised

www.shutterstock.com 1060794641







Why are even talking about that today..

https://linkinghub.elsevier.com/retri eve/pii/S0167814019329597







1c:5 months



1b:3 weeks

FIRST IN HUMAN I VOLUME 139, P18-22, OCTOBER 01, 2019

Treatment of a first patient with FLASH-radiotherapy

Published: July 11, 2019 • DOI: https://doi.org/10.1016/j.radonc.2019.06.019 • 🖲 Check for updates

.. "Our patient had a long history of localized RT (110 different irradiations in about 10 years) and doses needed to control the lesions were typically 20–21 Gy in 6–10 fractions. Despite these relatively low total doses, the <u>acute toxicity</u> of these treatments was found to be relatively severe in the context of the particular skin frailty of this patient, **with commonly 3–4 months for complete healing**."

The tumor started to shrink around 10 days after irradiation with a **complete tumor response at 36 days** which was durable for the subsequent 5 months





Why is it interesting?

RESULTS BY YEAR



70 pubs in 2021

Source PUBMED: articles with FLASH or UHDR in abs/title



.. because it works... and we do not (yet) understand why!

& INFN is the perfect place for giving a helping hand... as we need measurements... and for measurements we need:

- Accelerators capable of delivering FLASH beams
- Detectors capable of monitoring FLASH rates

And afterwards we need modeling and simulations to understand how much we can gain from it....



"Physics FLASH is like sex: sure, it may give some practical results, but that's not why we do it." – (based on.. Richard P. Feynman quote)

Not an easy task [that's why it's fun!]

Even discussing 'what is FLASH' proves to be difficult...

- High dose rate [100 Gy/s?].. And here a lot of discussion can start if you are talking about 'average' or 'instantaneous' dose rates... but to cut short along story → 2-3 OoM wrt current clinical practice
- Dose above a given threshold [4-6 Gy].. At the Organs at Risk (OARs)!



What are the options so far for 'clinical-like' FLASH beams:

- e-: beams with FLASH intensity are already available.. But at 'low energy'
- p: FLASH intensities are doable.. Problem is
- γ : only at specific synchrotron facilities and 40 Gy/s top... producing flash RT beams is proving to be really difficult!

3

+ something unexpected! [and actually FLASH unrelated]

e⁻ are 'back in the business'! [thanks to but independently of.. FLASH!]

- Nice prospects for compact acceleration to reach deep tumours
- Naturally provide SOBP @ fixed energy → good for FLASH!
- Can be easily accelerated @ FLASH rates [already done for low energies]
- Current best candidates for FLASH clinical translation [see slide 2!]



That's why.. there's FRIDA

INFN CSN5 call , ~ 1M€, 7 INFN units, 30 FTE, 100 people PI (A. Sarti) + WP2 coord (A. Mostacci) + WP4 coord (A. Schiavi) ... All from Roma1, all with A.

Links & Documents ¥

FRIDA goals

- Explore the time scales at which the FLASH effect occurs, refine the experimental characterization and modelling of the effect.
- Develop compact, high intensity sources and delivery solutions for EBRT with e- and p
- Explore novel detection strategies both for dosimetry and beam monitoring applications
- Assess the FLASH effect potential using dedicated MC simulations and an ad hoc modelling of the NT sparing to provide optimised treatments that can be compared with state of the art RT and PT results

Search ... <u>A</u> Sign In II III III <u>https://web.infn.it/FRIDA</u> FLASH Radiotherapy with high Dose-rate particle becams The FRIDA project

0 9 🖬

The external beam radiotherapy research community is currently experiencing an exciting time: experimental evidence is growing, supporting the evidence of a considerable normal tissue sparing effect when treatments are delivered with dose rates much larger (100 times or more) with respect to the conventional ones. If confirmed, this so-called 'FLASH effect' has the potential to re-shape the future of radiation treatments especially with charged particles, with a significant impact on many oncology patients. @RM1: De Gregorio,
 De Simoni, Ficcadenti,
 Franciosini, Giuliano,
 Marafini, Migliorati,
 Palumbo, Patera, Taini,
 Trigilio: 6.1 FTE

5



1st of all: Facilities now...



Upgrade of UNITO Linac and TIFPA p-Lab FLASH IORT @ PI

Electrons

- SIT: the company will give access to the FLASH machines (low energy) that are in development
- UNIPI: SIT IORT flash accelerator
- TO: a low energy linac
- PI: CNR-INO lab
- BTF @ LNF?

Protons

- CNAO: is making available the research room for FLASH testing and experimentation
- TIFPA: an upgrade of the IBA accelerator will be implemented along what already done in Dresden
- ELIMED /Queens (UK) beamlines

Everyone is eager to see some FLASH beam: FRIDA can represent quite of an opportunity

.. and then



The sapienza - INFN joint effort

The 'FLASH' wave brings the opportunity to build a research facility in Sapienza to test the accelerator prototype and study the FLASH effect & VHEE potential



Courtesy of V. Patera & L. Palumbo

Knowing the dose (dose-rate)

- Current technologies cannot be 'easily' adapted to cope with 3 OoM increase in dose rates while retaining same accuracy/precision: saturations and non-linearities are kicking in.
- Many attempts within FRIDA to provide solutions / upgrade of current technologies... @ RM1 we are pursuing a new approach: use induced air-fluorescence to monitor the beam & measure the dose/instantaneous dose rates

Courtesy of M. Marafini, G. Traini, A. Trigilio





While getting the tools ready to play.. (and some of them are really in an advanced state..) Before rushing.. We need thinking.. It's crucial that we clearly define what are the first things that we need to implement and explore from

FLASH != magic



Cannot be 'blindly' applied to all districts/pathologies!

Interaction with clinics is crucial: we can profit from the knowhow of a network built inside 'Scuola di Specializzazione in Fisica Medica' (A. Migliorati, V. Patera, A. Sarti), RM hospitals (Policlinico, San Camillo & CampusBiomedico), national and international treatment centres...

While getting the tools ready to play.. (and some of them are really in an advanced state..) Before rushing.. We need thinking.. It's crucial that we clearly define what are the first things that we need to implement and explore from the **a**) district **b**) radiation/beam delivery



- Choice of the district not easy: should be compliant with severe hypofractionation, there must be something to be gained wrt standard RT
- While p and γ have 50 (100) years of experience, e- for deep seated is rather new: planning is an entirely new game...

While getting the tools ready to play.. (and some of them are really in an advanced state..) Before rushing.. We need thinking.. It's crucial that we clearly define what are the first things that we need to implement and explore from the a) district b) radiation/beam delivery c) constraints Choice of the **Evaluating the dose** pathology and with Monte distributions is a computational acquisition of nightmare. Fast MC can help, Carlo the CT scans and but nevertheless you need to simulations constraints 'optimise' the fluence in a multiparametric space.. Fix the geometry Machine learning can help! **Optimisation of** treatment and (see talk from C. M. the beam beam fluences Terracciano) energies

While getting the tools ready to play.. (and some of them are really in an advanced state..) Before rushing.. We need thinking.. It's crucial that we clearly define what are the first things that we need to implement and explore from the **a**) district **b**) radiation/beam delivery **c**) constraints **d**) FLASH modeling points of view.



Front, Oncol., 23 December 2021 | https://doi.org/10.3389/fonc.2021.777852

Deep Seated Tumour Treatments With Electrons of High Energy Delivered at FLASH Rates: The Example of Prostate Cancer

🛃 Alessio Sarti^{1,2}, 😑 Patrizia De Maria³, 💂 Giuseppe Battistoni4, 🤏 Micol De Simoni²5, 🚊 Cinzia Di Felice⁶, 🙏 Yunsheng Dong⁴, 🐁 Marta Fischetti^{1,2}, 🙏 Gaia Franciosini^{2,5}, 🐁 Michela Marafini^{2,7}, Francesco Marampon⁸, 🗉 Ilaria Mattei⁴, 🙏 Riccardo Mirabelli²⁵, 🖄 Silvia Muraro⁴, 👘 Massimiliano Pacilio⁶, 🙏 Luigi Palumbo^{1,2}, 🙏 Loredana Rocca¹, 🖄 Damiana Rubeca¹, 🙏 Angelo Schiavi^{1,2*}, 🖄 Adalberto Sciubba¹⁹, 🖄 Vincenzo Tombolini⁸, 🖄 Marco Toppi¹⁹, 👘 Giacomo Traini², 👘 Antonio Trigilio^{2.5} and 🖳 Vincenzo Patera^{1.2}

> After a first 'proof of concept' exercise on prostate cancer, time came for a more interesting study: the head & neck district... **FIRST** example of low energy/small n. of fields example for VHEE



The H&N case

100

60

40

20

0

1000

2000



CONFRONTO TRA I VINCOLI DOSE-VOLUME

Organo		Protoni	Fotoni	VHEE
	$V_{95\%}$	100%	100%	99.44%
\mathbf{PTV}	$V_{100\%}$	90.62%	81.60%	67.41%
	$V_{105\%}$	0.01%	0.01%	1.16%
Nervi Ottici	D_{max}	53.52 GyRBE	54.36 GyRBE	55.61 GyRBE
Chiasma	D_{max}	53.60 GyRBE	54.19 GyRBE	54.59 GyRBE
Vie Ottiche Posteriori	D_{max}	53.81 GyRBE	54.30 GyRBE	55.13 GyRBE
Occhi	D_{max}	2.82 GyRBE	12.62 GyRBE	4.76 GyRBE
Tronco Encefalico	D_{max}	54.26 GyRBE	53.61 GyRBE	54.73 GyRBE
Arterie Carotidi	$V_{105\%}$	0.03%	9.17%	0.19%
			* ******	







PTV

Nervi Ottici

- Chiasma Vie Ott Post

Occhi

Tronco

6000





Going FLASH: the IOeRT case

DAR1

OAR2





Most likely first example of clinical translation of FLASH.. No TPS so far: being developed right now exploiting GPU fast MC + ecographic input / CT adaptation using breach images



(since now you're probably asleep..)

To satisfy the high expectations of splatter slides, I've just added at the end the 'future' of IOeRT: the treatment of prostate cancer. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287028/

Conclusions

•Exciting time ahead of us

We have the **tools and the knowledge to contribute to the field**: this is an excellent opportunity to contribute to a technology that has the potential to **re-shape the radiotherapy landscape**.. Starting from IOeRT!

Accelerators and detectors R&D

We need to provide access to **facilities and reliable dose measurements** that are the prerequisite for doing the experiments needed to decide the fate of the FLASH effect: the sooner the better! [and VHEE have a reason on their own]

MC simulations and computing

Solving the problem of evaluating the FLASH impact potential helps focusing the efforts in the correct direction: the key is the synergy with **fast MC simulation techniques** and solution of **optimisation problems in many dimensions**

Spare slides

A crucial role is played by the dose delivery time structure..

F. Romano et al., Medical Physics (Supplemental issue "FLASH radiotherapy: Current Status and Future Developments", edited by K. Parodi, J. Farr and D. J. Carlson.), under review

2019-2021 (!)

Transient Hypoxia (O₂ Depletion)

- G. Pratx, D. S. Kapp, A computational model of radiolytic oxygen depletion during FLASH irradiation and its effect on the oxygen enhancement ratio, PMB (2019)
- K. Petersson, et al. A quantitative analysis of the role of oxygen tension in FLASH radiotherapy, IJROBP (2020)
- G. Adrian, et al., The FLASH effect depends on oxygen concentration, Brit. J. Radiol. (2020)
- R. Abolfath, et al, "Oxygen depletion in FLASH ultra-high-dose-rate radiotherapy: A molecular dynamics simulation." *Med. Phys.* (2020).
- S. Zhou, et al. "Minimum dose rate estimation for pulsed FLASH radiotherapy: A dimensional analysis." Med. Phys. (2020).
- A. Hu, et al. "Oxygen depletion hypothesis remains controversial: a mathematical model of oxygen depletion during FLASH radiation."" subm.arXiv (2021)
- Zakaria, A. et al.. (2021). Transient hypoxia in water irradiated by swift carbon ions at ultra-high dose rates: implication for FLASH carbon-ion therapy. Canadian Journal of Chemistry,
- Zhu, H, et al. "Modeling of cellular response after FLASH irradiation: a quantitative analysis based on the radiolytic oxygen depletion hypothesis." arXiv subm.(2021).

Intertrack Effects

- A.M. Zakaria, et al. "Ultra-High Dose-Rate, Pulsed (FLASH) Radiotherapy with Carbon lons: Generation of Early, Transient, Highly Oxygenated Conditions in the Tumor Environment." *Rad. Res.* (2020).
- J. Ramos-Méndez, et al. "LET-Dependent Intertrack Yields in Proton Irradiation at Ultra-High Dose Rates Relevant for FLASH Therapy." Rad. Res. (2020).
- Alanazi, A., et al.. (2021). A computer modeling study of water radiolysis at high dose rates. Relevance to FLASH radiotherapy. Radiation research, 195(2), 149-162.

Labarbe et al 2020

Organic radical-radical recombination

- R. Labarbe, et al. "A physicochemical model of reaction kinetics supports peroxyl radical recombination as the main determinant of the FLASH effect." Radiother. Oncol. (2020
- D. R. Spitz, et. al., An integrated physico-chemical approach for explaining the differential impact of FLASH versus conventional dose rate irradiation on cancer and normal tissue responses, Radiother. Oncol. (2019)
- C. Koch, Re: Differential impact of FLASH versus conventional dose rate irradiation, Radiother. Oncol. (2020
- D. R. Spitz, et al, Response to Ling et al. regarding, Radiother. Oncol. (2020).
- D. Boscolo et al.. (2020). Impact of target oxygenation on the chemical track evolution of ion and electron radiation. International Journal of Molecular Sciences, 21(2), 424.
- D. Boscolo, et al. May oxygen depletion explain the FLASH effect? A chemical track structure analysis. Radiother Oncol, 162:68-75.
- Y. Lai et al "Modeling the effect of oxygen on the chemical stage of water radiolysis using GPU-based microscopic Monte Carlo simulations, with an application in FLASH radiotherapy" Phys Med Biol 2020

Immune system driven

- Zhou, G. (2020). Mechanisms underlying FLASH radiotherapy, a novel way to enlarge the differential responses to ionizing radiation between normal and tumor tissues. Radiation Medicine and Protection, 1(1), 35-40.
- Jin J. Y., et al. FLASH Dose Rate Effect on Circulating Immune Cells: A Potential Mechanism for FLASH-RT?. International Journal of Radiation Oncology, Biology, Physics, 2020, 108.3: S7.
- Jin, Jian-Yue, et al. "Ultra-high dose rate effect on circulating immune cells: A potential mechanism for FLASH effect?." Radiotherapy and Oncology 149 (2020): 55-62.

- Multiscale modelling of the FLASH effect
- Dedicated in vitro/ex vivo experiments

Task 1..3 a FLASH pulse Time to deliver 10 Gy CONV NTCP modeling 10 scale (µm) Time to deliver 10 Gy FLASH &tissue -10 Physical Homogeneous chemistry Stage response - TCP (CONV) TCP Enzimatic TCP (FLASH) Stage NTCP 10 repair NTCP (CONV) NTCP (FLASH) Chemical Stage (Heterogeneous) processes Biological Stage Relevant Spatial DMF Further chemical reactions Primary 10 (no memory of initial track) Biochemical Stage onization, excitation Diffusion and reaction of 10-2 transport of generated radical species econdar Pre-Chemical Stage Dissociation of electrons 10 excited/ionized 40 Dose (Gy) molecules 10 $10^{-14} 10^{-13} 10^{-12} 10^{-11} 10^{-10} 10^{-9} 10^{-8} 10^{-7} 10^{-6} 10^{-5} 10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0} 10^{1} 10^{2} 10^{-3} 10^{-4} 10^{-5} 10^{-1} 10$ 10-17 Time from radiation start (s) Weber, Scifoni, Durańte subm. Med Phys 20 Type of lealon - Lethal lealone: 77 Reparative lealons Type of lesion - Lethal lesions: xy Repairable lesions: xy Task 1.2 DNA damage 0.5repair ose deposit events kinetics 00-Time (hour A) Time evolution of lethal (x_i) and potentially lethal/repairable lesions (x_i) for a single instantaneous irradiation according to the first order equations of the DDRK used in the MKM. B) Generalization of the temporal evolution for an arbitrary time structured irradiation. The dotted vertical lines represent the energy deposition events in the cell nucleus due to the passage of ionizing particles pO:=7% Manganaro wt al Med Phys 2017 OH HO, OF H/0* H0; Cordoni et al. Rad Res 2021

Task1.1

Radiation Chemistry From hetero to homo

Boscolo et al. Radiother. Oncol. 2021

Beam Characteristics	CONV	FLASH
Dose Per Pulse Dp	~0.4 mGy	~1 Gy
Dose Rate: Single Pulse D _p	~100 Gy/s	~10 ⁵ Gy/s
Mean Dose Rate: Single Fraction Ď _m	~0.1 Gy/s	~ 100 Gy/s
Total Treatment Time T	~days/minutes	< 500 ms

Alle intensità FLASH, il rateo di dose istantaneo e la dose per impulso sono ordini di grandezza più elevati rispetto a quelli della radioterapia convenzionale.

I rivelatori attualmente utilizzati non permettono di monitorare adeguatamente un fascio erogato alle intensità FLASH.

Requisiti necessari per un monitor in modalità FLASH:

linearità con elevati ratei di dose;
risoluzione spaziale (mm);
monitoraggio online del fascio;
indipendenza dall'energia del fascio.

Rivelatori a **carica**: creazione e raccolta di cariche. **Scarsa risoluzione temporale**, **dipendenza dall'energia** e **saturazione** ad alte dosi.

Rivelatori **chimici**: materiali producono ioni e molecole se irradiati. **Scarsa risoluzione temporale**. Rivelatori luminescenti: generazione di fotoni ottici a seguito della radiazione.
TLD e OSLD: impurità nel reticolo cristallino creano dei centri di luminescenza.
Scintillatori: più rapidi di TLD e OSLD.
Radiazione Cherenkov: emissione NON isotropica di fotoni.

La **fluorescenza** presenta delle caratteristiche che rendono un **monitor di fascio** potenzialmente utile per soddisfare le richieste precedentemente elencate.

Radiazione incidente:

- •elettroni della materia eccitati dall'energia della radiazione;
- •gli elettroni passano ad uno stato instabile a più alta energia;
- •l'elettrone decade ad un livello energetico fondamentale ed emette un fotone di fluorescenza.

Resa di fluorescenza:

- •numero di fotoni emessi per elettrone e per unità di lunghezza del cammino.
- la resa (ph./m) di un elettrone è proporzionale a dE/dx ed è quasi indipendente dall'energia cinetica degli elettroni.

Il numero di fotoni di fluorescenza emessi a causa del passaggio di un elettrone è quasi piatto: **4 - 5** fotoni di fluorescenza nell'intervallo di energia **10 - 1000** MeV.

4 - 5 fotoni di fluorescenza per metro permettono di misurare i **10**¹⁰⁻¹² elettroni erogati in modalità FLASH senza avere problemi di **saturazione**.